Associated Papers
Cell cycle duration determines oncogenic transformation capacity.
Chen D et al.
Nature, 2025
Distinct outcomes from targeted perturbations of the multi-subunit SCFSkp2 E3 ubiquitin ligase in blocking Trp53/Rb1-null prostate tumorigenesis.
Xue Y et al.
Communications Biology, 2025
The Mitotic Checkpoint Complex controls the association of Cdc20 regulatory protein with the ubiquitin ligase APC/C in mitosis.
Sitry-Shevah D et al.
Proceedings of the National Academy of Sciences of the United States of America, 2024
Comprehensive single cell transcriptomics analysis of murine osteosarcoma uncovers Skp2 function in metastasis, genomic instability and immune activation and reveals additional target pathways.
Ferrena A et al.
Biorxiv : the Preprint Server for Biology, 2024
Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma.
Wang J et al.
Oncogene, 2024
Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.
Gupta P et al.
British Journal of Cancer, 2022
Regulation of p27 (Kip1) by Ubiquitin E3 Ligase RNF6.
Deshmukh D et al.
Pharmaceutics, 2022
A cancer-associated CDKN1B mutation induces p27 phosphorylation on a novel residue: a new mechanism for tumor suppressor loss-of-function.
Bencivenga D et al.
Molecular Oncology, 2021
Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer.
Zhao H et al.
Cancer Research, 2020
Caspases uncouple p27(Kip1) from cell cycle regulated degradation and abolish its ability to stimulate cell migration and invasion.
Podmirseg SR et al.
Oncogene, 2016
Skp2-macroH2A1-CDK8 axis orchestrates G2/M transition and tumorigenesis.
Xu D et al.
Nature Communications, 2015
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.
Agarwal A et al.
Blood, 2014
Rb suppresses human cone-precursor-derived retinoblastoma tumours.
Xu XL et al.
Nature, 2014
PCTAIRE1 phosphorylates p27 and regulates mitosis in cancer cells.
Yanagi T et al.
Cancer Research, 2014
Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity.
Lu Z et al.
Nature Communications, 2014
Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222.
Kothapalli D et al.
Atherosclerosis, 2013
Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27.
Yan Y et al.
Cell Cycle (georgetown, Tex.), 2011
Incomplete folding upon binding mediates Cdk4/cyclin D complex activation by tyrosine phosphorylation of inhibitor p27 protein.
Ou L et al.
The Journal of Biological Chemistry, 2011
Siah1/SIP regulates p27(kip1) stability and cell migration under metabolic stress.
Nagano Y et al.
Cell Cycle (georgetown, Tex.), 2011
An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.
Ceccarelli DF et al.
Cell, 2011
Cyclins, Cdks, E2f, Skp2, and more at the first international RB Tumor Suppressor Meeting.
Bremner R et al.
Cancer Research, 2010
Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.
Wang H et al.
Nature Genetics, 2010
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB.
Lin HK et al.
Nature Cell Biology, 2009
Differential regulation of the cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip1) by phosphorylation directed by the cyclin encoded by Murine Herpesvirus 68.
Yarmishyn A et al.
Experimental Cell Research, 2008
A mechanism misregulating p27 in tumors discovered in a functional genomic screen.
Garrett-Engele CM et al.
Plos Genetics, 2007
Spy1 enhances phosphorylation and degradation of the cell cycle inhibitor p27.
McAndrew CW et al.
Cell Cycle (georgetown, Tex.), 2007
Substrate recognition and ubiquitination of SCFSkp2/Cks1 ubiquitin-protein isopeptide ligase.
Xu S et al.
The Journal of Biological Chemistry, 2007
Mutations of phosphorylation sites Ser10 and Thr187 of p27Kip1 abolish cytoplasmic redistribution but do not abrogate G0/1 phase arrest in the HepG2 cell line.
Guan X et al.
Biochemical and Biophysical Research Communications, 2006
A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression.
Besson A et al.
Genes & Development, 2006
Oncogenic Ras blocks transforming growth factor-beta-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway.
Schepers H et al.
Experimental Hematology, 2005
The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase.
Deng X et al.
The Journal of Biological Chemistry, 2004
CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis.
Connor MK et al.
Molecular Biology of the Cell, 2003
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
Shin I et al.
Nature Medicine, 2002
Jab1 co-activation of c-Jun is abrogated by the serine 10-phosphorylated form of p27Kip1.
Chopra S et al.
The Journal of Biological Chemistry, 2002
Transfection of p27(Kip1) threonine residue 187 mutant type gene, which is not influenced by ubiquitin-mediated degradation, induces cell cycle arrest in oral squamous cell carcinoma cells.
Kudo Y et al.
Oncology, 2002
p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis.
Rodier G et al.
The Embo Journal, 2001
A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase.
Malek NP et al.
Nature, 2001
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.
Carrano AC et al.
Nature Cell Biology, 1999
Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.
Montagnoli A et al.
Genes & Development, 1999
Synthetic lethality-based targets for discovery of new cancer therapeutics.
Weidle UH et al.
Cancer Genomics & Proteomics, 0